- SPEAKERS -
Topic to be announced
David Reardon
Director of Neuro-oncology, Dana Farber Cancer Center, Harvard University
Topic to be announced
Ching C. Lau
Director of Pediatric Oncology, Connecticut University Children’s Hospital, USA
Topic to be announced
David Ellison
Chair of Pathology, St Jude Children’s Hospital, Memphis, USA
Topic to be announced
Houtan Noushmehr
Associate Professor, Henry Ford Hospital, Detroit
Topic to be announced
Jiguang Wang
Associate Professor, Hong Kong University of Science and Technology
Topic to be announced
Cong Li
Deputy Dean, School of Pharmacy, Fudan University
For enquiries, please contact H K Ng (hkng@cuhk.edu.hk)
HSBC
Hong Kong & Shanghai Brain Consortium
上海香港神經腫瘤協作網絡

HSBC

Hong Kong & Shanghai Brain Consortium
上海香港神經腫瘤協作網絡

HSBC

ABOUT

Hong Kong and Shanghai Brain Consortium (HSBC) is a consortium led by the brain tumor researchers at Huashan Hospital, Fudan University, Shanghai and Chinese University of Hong Kong. It is not a structural centre or a society. Rather, it is a network combining the strengths of Hong Kong and Shanghai brain tumor researchers to combat this terrible group of diseases. It is also a platform for data sharing among all researchers on the globe and for us to reach out to researchers in neuro-oncology internationally. See under DATASETS.

Huashan Hospital, Fudan University and Chinese University of Hong Kong have a long history of collaborative research on brain tumors. This reflects the long history of co-operation and simultaneous growth of both cities. Fudan University ranks 34th and Chinese University of Hong Kong 43rd in the world (QS ranking 2020).

The Neurosurgical Institute at Huashan Hospital is the premier neurosurgical centre in China and carries out annual resection of about 9,000 brain tumors of all kinds and from all ages. See Mao Y et al. World Neurosurgery 2011 (PMID 21600467 ) and Wang C et al. Neurosurgery 2008 (PMID 18496201 ). It hosts a biobank of international standard of about 3,000 gliomas, see Shi Z et al. Biopreserv Biobank 2015 (PMID 25686045 ) and Aibaidula et al. Cell Tissue Bank 2015 (PMID 24929994 ). Brain tumor research at Chinese University of Hong Kong has been led by H K Ng who is an Expert Panel Member of the WHO Classifications of 2007, 2016 and 2021.

We hold international conferences as well as molecular pathology workshops to foster international networkworking and collaboration.

Ying Mao and Peter Shi are neurosurgeons and Ying Mao is President of Huashan Hospital. H K Ng is an internationally well known pathologist. We welcome collaboration with all specialties, clinical and laboratory, from around the world. Naturally we can collaborate better in some areas and not as well in others. But please do contact us anytime ( hkng@cuhk.edu.hk ).

BACKGROUND FOR PUBLIC

Brain tumor is a very heterogenous group of tumors. Unlike other common cancers, it is at least 20-30 tumors even for the common types. The complete list of brain tumors as outlined by World Health Organization 2016 is much longer.

Brain tumor is an extremely deadly tumor. The commonest adult brain tumor, glioblastoma, is almost universally fatal and has a median survival of only 14-16 months even with the standard-of-care treatment. This is much worse than other common cancers nowadays. And in spite of enormous understanding of the biology of glioblastoma, there has been relatively little progress in terms of prolonging patient survival, not to mention cure.

Brain tumor is also the commonest solid cancer in children. Like many pediatric cancers, great strides were made in the treatment but survival improvement has stalled in the last thirty years. Yet there have been great advances in the understanding of the biology of medulloblastomas and other pediatric brain tumors.

Pediatric brain tumors are also unusual in that there are many small groups of rare tumors that even the best centres in the world do not have enough cases for good studies. So collaboration is a must to study these rare pediatric brain cancers. In Asia, germ cell tumor is also well known to be much commoner than in the west.

Meningiomas are another group of common brain tumor. Meningiomas do not usually cause death shortly but 5-10% of cases, in spite of the best surgical operations, will recur and multiple recurrences eventually cause great morbidity or death. There is no standard-of-care chemotherapy regimen for meningiomas.

The group of researchers of HSBC working in Shanghai and Hong Kong have great passion in helping patients with this group of terrible diseases. While we may not be publishing in Science or Nature, we do excellent research work comparable to many good international clinical centres. We have clinical and laboratory infrastructures comparing to many international clinical centres too. See click here click here

While the researchers of HSBC have their own national grants, we work closely with charities and industries who play very important roles in combating this group of diseases. If you are interested in sponsoring our work, please write us anytime ( hkng@cuhk.edu.hk ).

  OUR WORK

PEOPLE

ADVISORS

Mitch Berger

Mitch Berger

UCSF

Chris Jones

Chris Jones

Cancer Research UK

Patrick Wen

Patrick Wen

Dana Farber Cancer Institute

MEMBERS

  • Aden Chan, Chinese University of Hong Kong
  • Danny Chan, Chinese University of Hong Kong
  • Hong Chen, Huashan Hospital, Fudan University, Shanghai
  • Amanda Kan, Hong Kong Children's Hospital
  • Kay Li, Chinese University of Hong Kong
  • Anthony P Y Liu, Hong Kong University
  • Ying Mao, Huashan Hospital, Fudan University, Shanghai
  • Roger McLendon, Duke University, USA
  • Rawia Mohamed, Sheikh Shakhbout medical city, AbuDhabi
  • Ho-Keung Ng, Chinese University of Hong Kong
  • Wai S. Poon, Chinese University of Hong Kong
  • Zhifeng "Peter" Shi, Huashan Hospital, Fudan University, Shanghai
  • Eka Susanto, University of Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Tony S T To, Hong Kong Polytechnic University
  • Rui Ryan Yang, Guangzhou Children's Hospital, Guangzhou, China
  • Zhenyu Zhang, First Hospital, Zhengzhou, China
  • HKSAN (Hong Kong Student Association of Neuroscience)
  • OUR WORK

    EVENTS

    CONFERENCES & WORKSHOPS

    December 17, 2022

    April 30, 2022


    Number of registrants outside mainland China : 619
    Approximately an equal number in mainland China, run on a different internet

    October 30 2021
    「腦前行」 Braintrekking 2021

    October 21, 2021

    For scientific programme, please click here
    For free registration, please click here
    For enquiries, please contact H K Ng (hkng@cuhk.edu.hk)


    Number of registrants outside mainland China : 384
    Number of attendees inside mainland China: 1,780

    May 17-18 2019
    International Molecular Pathology Workshop, Gold Coast, Australia

    SPEAKERS
    David Ellison, Memphis, USA
    Alfred Lam, Gold Coast, Australia
    H.K. Ng, Hong Kong, China
    Arie Perry, San Francisco, USA
    Tom Robertson, Brisbane, Australia
    Peter Shi, Shanghai, China

    International Molecular Pathology Workshop, Gold Coast, Australia
    International Molecular Pathology Workshop, Gold Coast, Australia
    International Molecular Pathology Workshop, Gold Coast, Australia
    International Molecular Pathology Workshop, Gold Coast, Australia

    May 18-19, 2018
    International molecular pathology workshop, Hong Kong

    SPEAKERS
    Dan Brat, Chicago
    Godfrey Chan, Hong Kong
    Cynthia Hawkins, Toronto
    Ying Mao, Shanghai
    H K Ng, Hong Kong

    International molecular pathology workshop, Hong Kong
    International molecular pathology workshop, Hong Kong

    Regular bilateral research meetings

    Regular bilateral research meetings
    Regular bilateral research meetings
    ×

    ×

    Peter Zhifeng SHI

    Peter is a medical graduate of Shanghai Medical College and completed the residency training in neurosurgery at Huashan under the direct supervision of Academician Zhou Liang-fu. His indepth study of brain tumour pathology research with Professor H.K. Ng of The Chinese University of Hong Kong has started him on a productive path of glioma work. He has carried out Radiomics study in glioma with developing several noninvasive methods predicting molecular biomarkers based on MRI images. He has also worked on advanced biomaterials compatible for neurosurgical implant medical devices. His hard work has resulted in high citation publications in Radiology, Cell Research and Nature Communications. His research is well supported by the Shanghai City Government, National Natural Science Foundation of China (NSFC) and the Chinese 973 Projects.

    CONTACT

    Neurosurgical Institute, Huashan Hospital (Western Hospital), 958, Jinguang Road, Minhang District, Shanghai, China